Blinatumomab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.

**Synonyms:** - AMG 103 - AMG-103 - AMG103 - Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody - Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103 - BLINATUMOMAB - Blincyto - MEDI 538 - MEDI-538 - MEDI538 - MT 103 - MT-103 - MT103